Covered when the indication-specific objective findings and prior therapy history listed on the intake form are documented; the form collects the following grouped elements per indication.
Atopic dermatitis intake: Prescriber specialty (dermatologist, allergist, immunologist, other); therapeutic failure or intolerance to a generic topical corticosteroid and/or generic topical tacrolimus or pimecrolimus; inability to apply topical therapies due to extent of body surface area involvement; presence of severe atopic dermatitis with severely damaged skin; prior Dupixent use and whether positive clinical response was experienced
From atopic dermatitis section of form
Eosinophilic esophagitis (EoE) intake: Esophageal biopsy eosinophil count greater than or equal to 15 eos/hpf; clinical symptoms of esophageal dysfunction (for example dysphagia, food impaction, gastroesophageal reflux); history of EoE signs or symptoms; two or more episodes of dysphagia per week; therapeutic failure, contraindication, or intolerance to high-dose proton-pump inhibitor therapy; prior Dupixent use and, if yes, select responses (reduced symptom severity/frequency and/or histological remission <15 eos/hpf)>= 15 eos/hpf
From EoE section of form
Asthma intake: Baseline pre-bronchodilator FEV1; bronchodilator reversibility of at least 12% and 200 mL after albuterol; history of ≥2 asthma exacerbations requiring systemic corticosteroids in prior 12 months or ≥1 hospitalization for asthma in prior 12 months; blood eosinophil count ≥150 cells/µL; current use of daily or alternate-day oral corticosteroids (yes/no); inadequate control despite regular medium- or high-dose inhaled corticosteroid plus at least one additional controller; intent to continue ICS+controller while using Dupixent; prior Dupixent use and, if yes, select clinical responses (decreased rescue medication/oral steroid use, decreased exacerbation frequency, improved pulmonary function, reduced asthma symptoms)FEV1 reversibility >= 12% and >= 200 mL; blood eosinophils >= 150 cells/µL
From asthma section of form
Chronic rhinosinusitis with nasal polyposis (CRSwNP) intake: Baseline bilateral nasal polyp score (0–8) and baseline nasal congestion score (0–3); therapeutic failure, intolerance, or contraindication to an intranasal corticosteroid; therapeutic failure, intolerance, or contraindication to a 14‑day course of oral corticosteroids; prior Dupixent use and, if yes, select responses (decrease in nasal polyp score and/or nasal congestion severity)
From CRSwNP section of form
Prurigo nodularis intake: Prescriber specialty (dermatologist, allergist, immunologist, other); presence of at least 10 identifiable nodular lesions; therapeutic failure, intolerance, or contraindication to one generic topical corticosteroid; inability to apply topical therapies due to extent of BSA involvement; severely damaged skin; prior Dupixent use and, if yes, select responses (reduction in itch and/or reduction in number of nodules)
From prurigo nodularis section of form
COPD intake: Post-bronchodilator FEV1 percent predicted; blood eosinophil count; mMRC dyspnea scale score; current daily or alternate-day oral corticosteroid use; history of ≥2 moderate exacerbations treated with systemic corticosteroids and/or antibiotics in prior year or ≥1 severe exacerbation requiring hospitalization/observation >24 hours; classification as GOLD group E; inadequate symptom control despite ≥3 months of triple therapy (LAMA + LABA + ICS) or intolerance/contraindication to these agents; prior Dupixent use and, if yes, select responses (reduction in symptoms, improved exercise tolerance, delayed disease progression, reduction in exacerbations)
From COPD section of form
Chronic spontaneous urticaria (CSU) intake: Therapeutic failure, intolerance, or contraindication to antihistamines at maximum recommended doses (for example cetirizine, desloratadine, levocetirizine); prior Dupixent use and, if yes, whether member experienced improvement in CSU symptoms while on therapy
From CSU section of form